Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients Lin et al., "Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma," PLoS One, vol.
REVIEW Open Access Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia Mingxue Fan1, Minghao Li1, Lipeng Gao1, Sicong Geng2, Jing Wang1, Yiting Wang1, Zhiqiang Yan1* and Lei Yu1*
CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Authors: Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE; Issue date: 2014 Feb
Adoptive cell transfer therapy delivers immune cells to destroy cancer cells. Often the kind of immune cell that is transferred is a T-cell. This is a very potent immune cell that has the ability to kill cancer cells on contact. Learn more about how immunotherapy works.
Adoptive T Cell Therapy. Adoptive T cell therapy involves the isolation and ex vivo expansion of tumor specific T cells to achieve greater number of T cells than what could be obtained by vaccination alone. The tumor specific T cells are then infused into patients with cancer in an attempt to give their immune system the ability to overwhelm remaining tumor via T cells which can attack and kill cancer.
Jun 17, 2015 · Adoptive Cell ImmunoTherapy (ACT) is a personalized cancer therapy that consists of activating and expanding patients’ immune cells in vitro with direct anti-tumor activity, posteriorly reintroducing these cells back into the patient.
May 17, 2019 · However, for tumors in which an extant population of tumor-reactive T cells is absent or fails to function, adoptive cellular therapy or cancer vaccines can augment the population of antitumor effector cells. We review the novel strategies encompassing these approaches, including adoptive T-cell therapy and cancer vaccines targeting neoantigens, CAR T-cell therapy, and endogenous T-cell therapy.
Apr 05, 2017 · Her talk is titled “Engineering adoptive T cell therapy for efficacy in ovarian cancer. ” She was selected for a 2017 AACR Women in Cancer Research Scholar Award, a travel award given to female early-career cancer researchers presenting at the meeting.
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Richard A. Morgan, Laura A. Johnson, Jeremy L. Davis, Zhili Zheng, Kevin D Woolard , Elizabeth A. Reap, Steven A. Feldman, Nachimuthu Chinnasamy, Chien Tsun Kuan, Hua Song, Wei Zhang, Howard A. Fine, Steven A ...